Literature DB >> 26667829

Impact of GSTM1, GSTT1 and GSTP1 gene polymorphism and risk of ARV-associated hepatotoxicity in HIV-infected individuals and its modulation.

H O Singh1, S Lata1, M Angadi2, S Bapat2, J Pawar2, V Nema1, M V Ghate2, S Sahay2, R R Gangakhedkar2.   

Abstract

Glutathione S-transferase (GST) family is involved in a two-stage detoxification process of a wide range of environmental toxins, carcinogen and antiretroviral (ARV) therapy (ART) drugs. The aim of this study is to describe the impact of genetic polymorphisms of GSTM1, GSTT1 and GSTP1-313A/G in the risk of ARV-associated hepatotoxicity in HIV-infected individuals and its modulation in hepatotoxic patients. We enrolled a total of 34 patients with hepatotoxicity, 131 HIV-infected individuals without hepatotoxicity under non-nucleoside reverse transcriptase inhibitor containing ART and 153 unrelated healthy individuals. With a case-control design, polymorphisms of GSTM1, GSTT1 and GSTP1-313A/G gene were genotyped by PCR and restriction enzyme-length polymorphism. Genotypes of GSTT1 null were significantly higher in HIV-infected individuals as compared with healthy controls (P=0.01, odds ratio (OR)=1.54). HIV-infected individuals with GSTM1-null genotype showed higher risk (P=0.09, OR=1.37) for hepatotoxicity, but risk was not significant. On evaluating gene-gene interaction models, GSTM1 null and GSTT1 null showed significant association with the risk of hepatotoxicity in HIV-infected individuals (P=0.004, OR=2.67) owing to synergistic effect of these genes. Individuals with GSTT1-null and GSTM1-null genotypes showed higher risk of hepatotoxicity with advanced stage of (CD4<200) of HIV infection (P=0.18, OR=1.39; P=0.63, OR=1.13). In case-only analysis, GSTT1-null genotype among alcohol users showed elevated risk of hepatotoxicity in HIV-infected individuals (P=0.12, OR=1.36, 95% confidence interval (CI): 0.94-1.97) as compared with GSTT1 genotypes. The carriers GSTM1-null+GSTT1-null genotype among nevirapine user showed prominent risk of hepatotoxicity in HIV-infected individuals (P=0.12, OR=4.21, 95% CI: 0.60-29.54). Hence, we can conclude that GSTT1-null and GSTM1-null genotypes alone and in combination may predict the acquisition of hepatotoxicity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26667829     DOI: 10.1038/tpj.2015.88

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  40 in total

1.  Drug-induced liver injury: mechanisms and test systems.

Authors:  D M Bissell; G J Gores; D L Laskin; J H Hoofnagle
Journal:  Hepatology       Date:  2001-04       Impact factor: 17.425

Review 2.  A bird's eye view of the glutathione transferase field.

Authors:  B Ketterer
Journal:  Chem Biol Interact       Date:  2001-10-25       Impact factor: 5.192

3.  CYP1A1 genotype modifies the impact of smoking on effectiveness of HAART among women.

Authors:  David N Feldman; Joseph G Feldman; Ruth Greenblatt; Kathryn Anastos; Leigh Pearce; Mardge Cohen; Stephen Gange; Suzanne Leanza; Robbie Burk
Journal:  AIDS Educ Prev       Date:  2009-06

Review 4.  Glutathione S-transferase polymorphisms and colorectal cancer: a HuGE review.

Authors:  S C Cotton; L Sharp; J Little; N Brockton
Journal:  Am J Epidemiol       Date:  2000-01-01       Impact factor: 4.897

5.  Comparative study of GST polymorphism in relation to age in COPD and lung cancer.

Authors:  Rajni Kant Shukla; Surya Kant; Balraj Mittal; Sandeep Bhattacharya
Journal:  Tuberk Toraks       Date:  2013

6.  GSTT1 and GSTM1 null genotypes and the risk of gastric cancer: a case-control study in a Chinese population.

Authors:  V W Setiawan; Z F Zhang; G P Yu; Y L Li; M L Lu; C J Tsai; D Cordova; M R Wang; C H Guo; S Z Yu; R C Kurtz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-01       Impact factor: 4.254

7.  Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity.

Authors:  M Pirmohamed; A Alfirevic; J Vilar; A Stalford; E G Wilkins; E Sim; B K Park
Journal:  Pharmacogenetics       Date:  2000-11

8.  Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy.

Authors:  M Núñez; R Lana; J L Mendoza; L Martín-Carbonero; V Soriano
Journal:  J Acquir Immune Defic Syndr       Date:  2001-08-15       Impact factor: 3.731

9.  A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer.

Authors:  D J Hunter; S E Hankinson; H Hough; D M Gertig; M Garcia-Closas; D Spiegelman; J E Manson; G A Colditz; W C Willett; F E Speizer; K Kelsey
Journal:  Carcinogenesis       Date:  1997-11       Impact factor: 4.944

10.  Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children.

Authors:  Russell B Van Dyke; Lu Wang; Paige L Williams
Journal:  J Infect Dis       Date:  2008-12-01       Impact factor: 5.226

View more
  8 in total

1.  Lightning-fast genome variant detection with GROM.

Authors:  Sean D Smith; Joseph K Kawash; Andrey Grigoriev
Journal:  Gigascience       Date:  2017-10-01       Impact factor: 6.524

2.  The Association of HLA-B*35 and GSTT1 Genotypes and Hepatotoxicity in Thai People Living with HIV.

Authors:  Noppadol Chanhom; Jiraphun Jittikoon; Sukanya Wattanapokayakit; Surakameth Mahasirimongkol; Angkana Charoenyingwattana; Wanvisa Udomsinprasert; Usa Chaikledkaew; Supharat Suvichapanich; Taisei Mushiroda; Sasisopin Kiertiburanakul; Archawin Rojanawiwat; Wittaya Wangsomboonsiri; Weerawat Manosuthi; Pacharee Kantipong; Anucha Apisarnthanarak; Wilawan Sangsirinakakul; Pawinee Wongprasit; Romanee Chaiwarith; Woraphot Tantisiriwat; Somnuek Sungkanuparph; Wasun Chantratita
Journal:  J Pers Med       Date:  2022-06-08

3.  Genetic polymorphism of drug metabolism enzymes (GSTM1, GSTT1 and GSTP1) in the healthy Malian population.

Authors:  Yaya Kassogue; Brehima Diakite; Oumar Kassogue; Issa Konate; Kadidiatou Tamboura; Zoumana Diarra; Hind Dehbi; Sellama Nadifi; Cheick Bougadari Traore; Sounkalo Dao; Seydou Doumbia; Guimogo Dolo
Journal:  Mol Biol Rep       Date:  2019-10-24       Impact factor: 2.316

4.  Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility.

Authors:  Cinzia Ciccacci; Andrea Latini; Cristina Politi; Sandro Mancinelli; Maria C Marazzi; Giuseppe Novelli; Leonardo Palombi; Paola Borgiani
Journal:  Eur J Clin Pharmacol       Date:  2017-07-08       Impact factor: 3.064

5.  Homozygous deletion of both GSTM1 and GSTT1 genes is associated with higher CD4+ T cell counts in Ghanaian HIV patients.

Authors:  Joshua Agbemefa Kuleape; Emmanuel Ayitey Tagoe; Peter Puplampu; Evelyn Yayra Bonney; Osbourne Quaye
Journal:  PLoS One       Date:  2018-05-24       Impact factor: 3.240

6.  Association of glutathione S-transferases (GSTT1, GSTM1 and GSTP1) genes polymorphisms with nonalcoholic fatty liver disease susceptibility: A PRISMA-compliant systematic review and meta-analysis.

Authors:  Yi Zhu; Jian-Hua Yang; Jun-Ping Hu; Ming Qiao
Journal:  Medicine (Baltimore)       Date:  2022-09-23       Impact factor: 1.817

7.  Correlations between Low Doses of Zearalenone, Its Carryover Factor and Estrogen Receptor Expression in Different Segments of the Intestines in Pre-Pubertal Gilts-A Study Protocol.

Authors:  Magdalena Gajęcka; Magdalena Mróz; Paweł Brzuzan; Ewa Onyszek; Łukasz Zielonka; Karolina Lipczyńska-Ilczuk; Katarzyna E Przybyłowicz; Andrzej Babuchowski; Maciej T Gajęcki
Journal:  Toxins (Basel)       Date:  2021-05-26       Impact factor: 4.546

Review 8.  The Glutamate System as a Crucial Regulator of CNS Toxicity and Survival of HIV Reservoirs.

Authors:  Anna Maria Gorska; Eliseo A Eugenin
Journal:  Front Cell Infect Microbiol       Date:  2020-06-24       Impact factor: 5.293

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.